Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.

Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors resistant to current treatments. PYXS's lead product ...

Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate (ADC) biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty ...

While one might expect a positive readout from a biotech’s lead candidate to boost the company’s stock price, Pyxis Oncology’s shares—which have tumbled more than 40% this week—tell a different story.